| Gemcitabine studied in …STUDIED_INderived10 of 2,012show all (up to 200) |
|---|
| → studied in | NCT03418038Phase 2 · recruiting Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia · 2,012 trials list this drug (440 active) | — | — | Lymphoma,Hodgkin Lymphoma,Chronic Myelomonocytic Leukemia+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03734029Phase 3 · completed Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04] · 2,012 trials list this drug (440 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05007106Phase 2 · completed MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) · 2,012 trials list this drug (440 active) | — | — | Esophageal Neoplasm,Gastric Neoplasm,Gallbladder Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05482893Phase 1/Phase 2 · recruiting Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study) · 2,012 trials list this drug (440 active) | — | — | Malignant Biliary Tract Neoplasm,Malignant Colorectal Neoplasm,Pancreatic Ductal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05712356Phase 2 · completed A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors · 2,012 trials list this drug (440 active) | — | — | Intrahepatic Cholangiocarcinoma,Malignant Bile Duct Neoplasm,Malignant Gallbladder Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06619236Phase 3 · active not recruiting Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer · 2,012 trials list this drug (440 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06623422Phase 3 · recruiting A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) · 2,012 trials list this drug (440 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06694454Phase 1/Phase 2 · suspended Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC) · 2,012 trials list this drug (440 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06770582Phase 2 · recruiting Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial · 2,012 trials list this drug (440 active) | — | — | Malignant Bladder Neoplasm,Non-Muscle Invasive Bladder Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06788912Phase 2 · active not recruiting Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01) · 2,012 trials list this drug (440 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |